Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings
RLMD·Reported May 8, 2024·After market close
Diluted EPS came in at $-0.72, beat the $-0.90 consensus by $0.18.
Diluted EPS
$-0.72beat by $0.18
Consensus: $-0.90
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Relmada Therapeutics, Inc.'s Q1 2024 earnings report.
Relmada Therapeutics, Inc. (RLMD) reported Q1 2024 earnings on May 8, 2024 after market close.
Relmada Therapeutics, Inc. reported diluted EPS of $-0.72 for Q1 2024.
EPS beat the consensus estimate of $-0.90 by $0.18.
You can read the 10-Q periodic report (0001213900-24-040856) directly on SEC EDGAR. The filing index links above go to sec.gov.